anoth partnership hopper lift target
anoth program ad pipelin alreadi plenti
opportun holiday therav announc
enter global licens agreement rate
therav preclin program skin-target locally-act
pan-janu kinas jak inhibitor compound specif
design possess skin-select activ minim system
exposur reduc elimin risk associ jak
class term agreement therav receiv
up-front cash payment million elig receiv
addit million develop sale mileston payment
addit agreement call therav receiv
royalti world-wide net sale potenti product emerg
program compani disclos indic
would focu develop effort number drug
candid although think psoriasi atop dermat would
logic target sinc jak mechan demonstr efficaci
treat diseas current develop inhibitor
abrocitnib atop dermat tyrosin kinas
inhibitor develop psoriasi abrocitinib
grant breakthrough therapi design fda februari
report success phase result given
context strike us unlik would pursu therav
partnership unless molecul provid compel result term
efficaci safeti preclin test ad program
valuat model therav take price target
sinc partnership provid import valid
program look leverag jak-class demonstr efficaci
although need improv safeti on-market
xeljanz tofacitinib alreadi demonstr impress efficaci treat
psoriasi although safeti profil suffici warrant
approv snda add psoriasi drug label receiv
complet respons letter despit setback xeljanz
deliv promis efficaci bid dose patient
achiev reduct pasi score baselin
achiev iga clear almost clear moreov efficaci
maintain patient month
get readi action-pack within coverag
therav stand sheer number catalyst expect
arguabl greatest signific phase
induct mainten studi uc rhea phase induct
studi cd indic dion expect readout
posit data would like catalyst janssen opt-into
program also therav recent began part program
asthma aim assess drug abil reduc fraction
exhal nitric oxid feno establish biomark
asthma part design assess addit biomark
sever asthmat result anticip patient
higher level feno mild asthma cohort per protocol
patient also bronchoscopi compani see
reduc marker inflamm therav recent
began phase lung allergen challeng expect result sometim
therav continu two phase trial ampreloxetin
program data first phase trial sequoia
expect
definit distribut analyst rate analyst certif disclosur pleas refer page report
valuat risk new price target therav base sum-of-the-part npv valuat base
compani commerci yupelri trelegi royalti stream core develop pipelin asset
ampreloxetin dcf model util termin declin rate wacc-bas discount rate base
compani wacc beta equiti risk premium adjust pipelin asset probabl success
uc cd indic ampreloxetin dermatolog program partner
phase develop believ proven mechan action warrant
strong probabl success believ probabl success ampreloxetin appropri sinc phase
develop strong phase data believ probabl success appropri sinc remain
rel earli stage develop even though jak mechan control inflamm well-establish
dermatolog program earliest stage develop although partnership give import valid
view regard commerci potenti probabl success assign probabl success trelegi
alreadi approv although maxim valu hing label expans strength captain data give us confid
occur next year risk includ clinic develop key pipelin asset commerci execut yupelri
financi sinc therav carri debt effort hing partner elect continu develop
collabor licens revenu
research develop
sell gener administr
incom invest
interest incom net
incom loss incom tax provis
share consid dilut ep calcul
probabl success assumpt
add cash equival
assum convert note debt
number fulli dilut outstand share
good sold
research develop expens
sell gener administr expens
incom invest
depreci amort
chang work capit
free cash flow firm
npv futur cash flow
npv termin valu
add cash equival
impli market valu firm
probabl success aggreg
npv
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori therav biopharma inc tbph-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
dougla tsao certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli relat
specif recommend view express research report neither member household
offic director advisori board member compani
none research analyst research analyst household financi interest secur therav
biopharma inc includ without limit option right warrant futur long short posit
decemb neither firm affili benefici class common equiti secur
therav biopharma inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market therav biopharma inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
